Bresat Cancer Update
Oncology Leader CommentarySpecial FeaturesPrevious Issues

Home: Oncology Leader Commentary: J. Michael Dixon, MD

Click on the topic below for comments by Dr J. Michael Dixon to comment on. You will also find links to related articles and clinical trials.

Breast cysts as a cancer risk factor
Biochemistry of breast cysts
Intratumoral estrogen levels in breast cancer
Neoadjuvant endocrine therapy
Response rates with neoadjuvant endocrine therapy
Time to response with neoadjuvant endocrine therapy
Randomized trials of neoadjuvant Arimidex
Response criteria with neoadjuvant therapy
Biologic effect of endocrine agents
Combining endocrine agents
Quality of life with neoadjuvant endocrine therapy
Neoadjuvant endocrine therapy of locally advanced breast cancer
Neoadjuvant therapy of inflammatory breast cancer
Neoadjuvant therapy of elderly patients
Timing of surgery after neoadjuvant therapy
Neoadjuvant therapy with aromatase inhibitors

Quality of life with neoadjuvant endocrine therapy

Play Audio Below:

What has always impressed me about neoadjuvant endocrine therapy is that you can achieve – I would say – a similar change in tumor volume over a slightly longer period of time with much less side effects if you select your patients properly. I think what’s interesting is we’ve done some quality of life studies – psychology studies – and patients don’t mind taking neoadjuvant endocrine therapy for a few months. Their quality of life is tremendous. The number of women that have side effects is very small because these are an elderly population, who get very few side effects from tamoxifen and anastrozole. So, they think it’s great.

Relevant Articles:

The primary use of endocrine therapies. [Review]
Howell A. Anderson E. Blamey R. Clarke RB. Dixon JM. Dowsett M. Johnston SR. Miller WR. Nicholson R. Robertson JF. Recent Results in Cancer Research. 152:227-44, 1998.

Top of Page

Home · Contact us
Terms of use and general disclaimer